All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, March 5, 2021
Home » Blogs » BioWorld MedTech Perspectives » Device user fee discussions heading nowhere fast

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech / FDA

Device user fee discussions heading nowhere fast

July 29, 2011
By Mark McCarty
No Comments

If you enjoy participating vicariously in exercises in futility, take a gander at what's going on in Washington with regard to user fees for medical device reviews.

Yesterday, Sen. Richard Burr (R-North Carolina) told FDA commish Margaret Hamburg, MD, than any user fee legislation that does not incorporate non-FDA days into the calculation of total 510(k) review days would face “a long and laborious process” to get the required legislation through the Senate Health, Education, Labor and Pensions Committee.

Burr's position was essentially that FDA has not met the turn-around on applications called for in the previous user fee handshake, which FDA blames on incomplete and poor-quality filings. What FDA never bothers to explain is how the quality of 510(k) submissions suddenly got so bad when Jeff Shuren, MD, took over at the Center for Devices and Radiological Health.

When industry previously complained that FDA reviewers are too fond of asking for more data than they need, FDA managers initially dismissed the complaints, but they have recently have acknowledged that it does happen.

Still, it's tough for industry to forget Shuren's claim in February that the longer turn-around times are “all on industry.” His “guinea pig” comment about patients in Europe will also live in infamy after he leaves the agency. Then at the annual meeting of the Medical Device Manufacturers Association earlier this year, he complained about the combative tone in Washington.

Sure the atmosphere in Washington is hot, and it's not just because this place was built on a swamp. But Shuren had nothing to do with that, right?

The June 27 user fee meeting between FDA and industry didn't go so well, either. As reported in the July 18 edition of Medical Device Daily, industry and the agency appear to have agreed in principal on an external audit of device reviews, but industry choked on the FDA proposal to boost user fees 17% between 2012 and 2013.

The conflict there is that the entire agency's budget is going to get a good haircut starting in fiscal 2012 and CDRH won't escape the shears, but industry is assuredly averse to paying a bunch more for the same kind of combative relationship and the same turn-around times.

Whether industry will respond to the implicit demand to pay up or watch the applications slow down even more when the layoffs start is tough to forecast, but third-party reviewers don't seem ready to fill in the gaps. It's the classic rock-and-a-hard-place scenario.

We've all been on a merry-go-round at least once. I hope so, anyway. As children we don't put any thought into the fact that while it really is a blast to get all dizzy and such, the ride ends without anyone having really gone anywhere. Hopefully nobody ends up with an upset stomach, though.

The difference in user fee negotiations is that the sensation it produces is not a fun kind of dizziness, and the upset stomach might be kicking the daylights out of someone's ulcer. The similarity? By the end of a day's work, you are more or less where you were when the ride started.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 4.
  • Gloved hand places sample tubes in PCR system

    COVID-19 test makers are adapting for variants

    BioWorld MedTech
    As COVID-19 variants have emerged, so have questions about the effectiveness of tests for infection. While the risk of mutations significantly limiting their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for March 4.
  • Celltrion-Regkirona-2-9

    Celltrion wins first conditional Korean approval for COVID-19 antibody Regkirona

    BioWorld
    HONG KONG – Celltrion Inc. has received conditional marketing authorization from the Ministry of Food and Drug Safety (MFDS) for its anti-COVID-19 monoclonal...
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing